| Serotonin model of schizophrenia: emerging role of glutamate mechanisms GK Aghajanian, GJ Marek Brain research reviews 31 (2-3), 302-312, 2000 | 657 | 2000 |
| Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments JH Krystal, G Sanacora, H Blumberg, A Anand, DS Charney, G Marek, ... Molecular psychiatry 7 (1), S71-S80, 2002 | 629 | 2002 |
| Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells GK Aghajanian, GJ Marek Neuropharmacology 36 (4-5), 589-599, 1997 | 589 | 1997 |
| 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex VA Vaidya, GJ Marek, GK Aghajanian, RS Duman Journal of Neuroscience 17 (8), 2785-2795, 1997 | 574 | 1997 |
| Serotonin and hallucinogens GK Aghajanian, GJ Marek Neuropsychopharmacology 21 (2), 16S-23S, 1999 | 530 | 1999 |
| Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release GK Aghajanian, GJ Marek Brain research 825 (1-2), 161-171, 1999 | 447 | 1999 |
| Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex GJ Marek, RA Wright, DD Schoepp, JA Monn, GK Aghajanian Journal of Pharmacology and Experimental Therapeutics 292 (1), 76-87, 2000 | 338 | 2000 |
| Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders GJ Marek, LL Carpenter, CJ McDougle, LH Price Neuropsychopharmacology 28 (2), 402-412, 2003 | 336 | 2003 |
| 5-HT2A receptor or α1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex GJ Marek, GK Aghajanian European journal of pharmacology 367 (2-3), 197-206, 1999 | 263 | 1999 |
| LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. GJ Marek, GK Aghajanian Journal of Pharmacology and Experimental Therapeutics 278 (3), 1373-1382, 1996 | 192 | 1996 |
| Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? GJ Marek, B Behl, AY Bespalov, G Gross, Y Lee, H Schoemaker Molecular pharmacology 77 (3), 317-326, 2010 | 189 | 2010 |
| Metabotropic glutamate receptors in the control of mood disorders JM Witkin, GJ Marek, BG Johnson, DD Schoepp CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2007 | 184 | 2007 |
| Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors JC Gewirtz, GJ Marek Neuropsychopharmacology 23 (5), 569-576, 2000 | 183 | 2000 |
| A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex GJ Marek, RA Wright, JC Gewirtz, DD Schoepp Neuroscience 105 (2), 379-392, 2001 | 173 | 2001 |
| Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures N Hiroi, GJ Marek, JR Brown, H Ye, F Saudou, VA Vaidya, RS Duman, ... Journal of Neuroscience 18 (17), 6952-6962, 1998 | 167 | 1998 |
| Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons GJ Marek, G Vosmer, LS Seiden Brain research 513 (2), 274-279, 1990 | 165 | 1990 |
| Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. LS Seiden, DL Commins, G Vosmer, K Axt, G Marek Annals of the New York Academy of Sciences 537, 161-172, 1988 | 150 | 1988 |
| A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action GJ Marek, CJ McDougle, LH Price, LS Seiden Psychopharmacology 109, 2-11, 1992 | 143 | 1992 |
| The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine GJ Marek, R Martin-Ruiz, A Abo, F Artigas Neuropsychopharmacology 30 (12), 2205-2215, 2005 | 140 | 2005 |
| Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? DD Schoepp, GJ Marek Current Drug Targets-CNS & Neurological Disorders 1 (2), 215-225, 2002 | 126 | 2002 |
